Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL22582364 | 1.00 | MEN1 (0.69) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL5314604 | 0.97 | MEN1 (0.75) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL11883179 | 0.97 | MEN1 (0.65) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL9400799 | 0.97 | MEN1 (0.75) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL1932496 | 0.97 | MEN1 (0.73) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL622411 | 0.94 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL9400796 | 0.94 | MEN1 (0.71) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL27478132 | 0.94 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL19992556 | 0.94 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL1824995 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| EP-0785765-B1 | AGENT AND PROCESS FOR PERMANENTLY SHAPING KERATIN FIBRES | HENKEL KGAA (DE) | 2002-04-03 | — | — | EP | disclosed |
| EP-0785765-A1 | AGENT AND PROCESS FOR PERMANENTLY SHAPING KERATIN FIBRES | Henkel Kommanditgesellschaft auf Aktien (DE) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996010986-A1 | AGENT AND PROCESS FOR PERMANENTLY SHAPING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1996-04-18 | — | — | WO | disclosed |
| US-3989640-A | SYNERGISTIC, MORPHOLINE, AMMONIUM BENZOATE AND CYCLOHEXANE OR NITROPROPANE OR CYCLOPENTENE | THE DRACKETT COMPANY (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250770-A1 | Fused heterocyclic compounds | IL2, IL4, IL15 | MEN1 1246/4885KMT2A 2143/4885KDM4E 3523/4885 |
| US-20090253694-A1 | Fused hetrocyclic compounds | IL2, IL15, IL4 | MEN1 1345/4885KMT2A 2644/4885KDM4E 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.